Graduate certificates and ala carte courses that meets the course requirements for a degree such as Master’s or Ph.D.
Published in Chapter:
Lessons Learned From the COVID-19 Pandemic and the Implications for Pharmaceutical Graduate Education and Research
Alok Bhushan (Jefferson College of Pharmacy, Thomas Jefferson University, USA), Kimberly B. Garza (Harrison School of Pharmacy, Auburn University, USA), Omathanu Perumal (College of Pharmacy and Allied Health Professions, South Dakota State University, USA), Sudip K. Das (College of Pharmacy and Health Sciences, Butler University, USA), David J. Feola (College of Pharmacy, University of Kentucky, USA), Dorothy Farrell (American Association of Colleges of Pharmacy, USA), and Angela Birnbaum (College of Pharmacy, University of Minnesota, USA)
Copyright: © 2022
|Pages: 22
DOI: 10.4018/978-1-7998-7623-6.ch014
Abstract
The COVID-19 pandemic has resulted in changes in the way we teach at all levels of education globally. This chapter specifically focusses on the impact of COVID-19 pandemic on MS and PhD programs in pharmaceutical sciences in schools/colleges of pharmacy in the United States. Potential expectations to bring the pandemic in control by rolling out the vaccine gives us hope, but there is an unmet need of medicines to treat patients affected by the disease. The impact of the pandemic on pharmaceutical sciences education has been on the pedagogy of teaching, research, mentoring, writing, and enrollment. This has also affected the progression of students in their programs as well as their stress levels and well-being. The role of administrators and accreditation agencies is critical in supporting graduate education by providing leadership and directions for the successful outcomes of these programs. Challenges and opportunities for these graduate programs are discussed in this chapter.